Affordable Access

deepdyve-link
Publisher Website

Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.

Authors
  • Masuda, Daisaku1
  • Miyata, Yuko2
  • Matsui, Shingo2
  • Yamashita, Shizuya3
  • 1 Rinku General Medical Center, Izumisano, Osaka, Japan. Electronic address: [email protected] , (Japan)
  • 2 Takeda Pharmaceutical Company Limited, Tokyo, Japan. , (Japan)
  • 3 Rinku General Medical Center, Izumisano, Osaka, Japan; Departments of Community Medicine and Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. , (Japan)
Type
Published Article
Journal
Atherosclerosis
Publication Date
Nov 19, 2019
Volume
292
Pages
163–170
Identifiers
DOI: 10.1016/j.atherosclerosis.2019.11.014
PMID: 31809985
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We aimed to investigate blood lipid and lipoprotein profiles in patients with dyslipidemia receiving hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) after 8 weeks of omega-3 fatty acid ethyl esters (Omega-3) treatment, using high-performance liquid chromatography with highly-sensitive gel filtration columns. In this phase 4, randomized, open-label study, patients with dyslipidemia receiving statins were randomized 1:1 to Omega-3 treatment (oral Omega-3 2 g twice daily) or Control (no Omega-3). Primary endpoint was change in mean particle size of low-density lipoprotein (LDL) and small dense LDL (cholesterol monitoring) in the specific 20-lipoprotein fraction assay. Secondary endpoints included changes in lipids, apolipoproteins, and lipoprotein concentrations in fasting blood. Changes were compared between treatments using analysis of covariance, adjusted by baseline fasting triglycerides and age. Fifty-three patients were randomized (Omega-3, n = 24; Control, n = 29). The difference in LDL particle size between Omega-3 and Control groups was significant at week 8 (p = 0.0040). Differences in least squares mean change in concentration from baseline to week 8 between Omega-3 and Control groups were significant for total cholesterol (p = 0.0009), LDL-C (p = 0.0442), non-high-density lipoprotein cholesterol (p = 0.0009), and remnant lipoprotein-cholesterol (p = 0.0396). Differences were significant for apolipoproteins AI, AII, B, B-48, B-100, CII, CIII, and CII/III, but not apolipoprotein E. Significant increases in LDL particle sizes and significant decreases in blood lipid, lipoprotein and apolipoprotein concentrations were observed with Omega-3 compared with Control. Omega-3 may improve blood lipid profile and increase LDL particle size, resulting in an anti-atherogenic profile. Copyright © 2019. Published by Elsevier B.V.

Report this publication

Statistics

Seen <100 times